Survival to 42 days by dose group of patients enrolled in the RING trial. The high-dose group (n = 29) included all subjects in the transfusion arm who received a mean dose of ≥0.6 × 109 granulocytes/kg and transfusion and had data available on the primary outcome (red line); the low-dose group (n = 13) included all subjects in the transfusion arm who received a mean dose of <0.6 × 109 granulocytes/kg and transfusion and had data on the primary outcome (blue line); the control group for this comparison (n = 43) included subjects in the control arm who received no transfusions and had data on the primary outcome (black line). The figure is a modification of Figure 6 in the article by Price et al that begins on page 2153. Figure prepared by Patrick Lane, ScEYEnce Studios.
